Does estrogen/progestin therapy in post-menopausal women decrease their risk of fracture?
Groh
K W
KW
Department of Family and Community Medicine, Columbia, Missouri, USA. grohk@health.missouri.edu
Stevermer
J J
JJ
D000367:Age Factors; D000368:Aged; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005260:Female; D050723:Fractures, Bone / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000150:complications* / Q000517:prevention & control*; D017698:Postmenopause / Q000187:drug effects*; D045167:Progesterone Congeners / Q000627:therapeutic use*; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D004966:Estrogens, Conjugated (USP); D045167:Progesterone Congeners; D017258:Medroxyprogesterone Acetate